Citations

Mayo Clinic

Showing 10 of 108599 citations.

Updated ultrafast dynamic computed tomography myelography technique for cerebrospinal fluid leaks
Mark, Ian T. , Madhavan, Ajay A. , Benson, John C. , Verdoorn, Jared T. , Yu, Lifeng , Benson, John , Mark, Ian , Madhavan, Ajay A , Yu, Lifeng

Interventional Neuroradiology | August 22, 2023 | Volume: 32 | Issue: 3 | Pages: 1160-1163

10.1177/15910199231193463 | PMID 37606552 Get It

We present an updated ultrafast dynamic computed tomography myelography technique that can be used for the localization of spontaneous spinal cerebrospinal fluid leaks in the setting of spontaneous intracranial hypotension. This has over twice the temporal resolution of previously described techniques at the same radiation dose output.
Premium Intraocular Lenses in Glaucoma—A Systematic Review
Hong, Ashley Shuen Ying , Ang, Bryan Chin Hou , Dorairaj, Emily , Dorairaj, Syril , Ang, Bryan C H

Bioengineering | August 22, 2023 | Volume: 10 | Issue: 9 | Pages: 993

10.3390/bioengineering10090993 | PMID 37760095 Get It

The incidence of both cataract and glaucoma is increasing globally. With increasing patient expectation and improved technology, premium intraocular lenses (IOLs), including presbyopia-correcting and toric IOLs, are being increasingly implanted today. However, concerns remain regarding the use of premium IOLs, particularly presbyopia-correcting IOLs, in eyes with glaucoma. This systematic review evaluates the use of premium IOLs in glaucoma. A comprehensive search of the MEDLINE database was performed from inception until 1 June 2023. Initial search yielded 1404 records, of which 12 were included in the final review of post-operative outcomes. Studies demonstrated high spectacle independence for distance and good patient satisfaction in glaucomatous eyes, with positive outcomes also in post-operative visual acuity, residual astigmatism, and contrast sensitivity. Considerations in patient selection include anatomical and functional factors, such as the type and severity of glaucomatous visual field defects, glaucoma subtype, presence of ocular surface disease, ocular changes after glaucoma surgery, and the reliability of disease monitoring, all of which may be affected by, or influence, the outcomes of premium IOL implantation in glaucoma patients. Regular reviews on this topic are needed in order to keep up with the rapid advancements in IOL technology and glaucoma surgical treatments.
Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam
Brunton, Joshua , Theiler, Regan N. , Mehta, Ramila A. , Enninga, Elizabeth Ann L. , Torbenson, Vanessa E. , Brunton, Joshua S , Mehta, Ramila, Branda, Megan E. , Enninga, Elizabeth Ann L , Theiler, Regan

Viruses | August 22, 2023 | Volume: 15 | Issue: 9 | Pages: 1782

10.3390/v15091782 | PMID 37766189 Get It

Congenital rubella syndrome is a constellation of birth defects that can have devastating consequences, impacting approximately 100,000 births worldwide each year. The incidence is much lower in countries that routinely vaccinate their population. In the US, postnatal immunization of susceptible women is an important epidemiological strategy for the prevention of rubella as the Center for Disease Control (CDC) does not recommend administering this vaccine during pregnancy due to its nature as a live attenuated virus vaccine. However, concerns that the co-administration of rubella vaccine with other immunoglobins (i.e., Rhogam) could compromise vaccine efficacy has produced warnings that can delay the administration of rubella vaccination postpartum, leaving women susceptible to the disease in subsequent pregnancies. We aimed to address whether the co-administration of the measles, mumps, and rubella (MMR) vaccine and Rhogam decreased antibody responses compared to those receiving only MMR vaccination. This retrospective cohort study utilized clinical data from 78 subjects who received the MMR vaccine and Rhogam after delivery and 45 subjects who received the MMR vaccine alone. Maternal demographics, pregnancy complications and rubella status at the start of a subsequent pregnancy were recorded for analysis. Overall, the two cohorts had similar baseline characteristics; however, lower parity was noted in the participants that received both MMR vaccination and Rhogam. Making assessments based on maternal antibody IgG index for rubella during the next pregnancy, we observed that 88% of the Rhogam + MMR vaccine group had positive serology scores, which was not significantly different from the 80% rate in the MMR-vaccine-only cohort (p = 0.2). In conclusion, no differences were observed in rubella immunity status in subsequent pregnancies in those mothers given both the MMR vaccine and Rhogam concurrently. Given these findings, warnings against co-administration of vaccines in combination with Rhogam appear unwarranted.
Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study
Naranjo, Mario , Jacob, Miriam , Hill, Nicholas S. , Larive, A. Brett, Finet, J. Emanuel , Erzurum, Serpil C. , Beck, Gerald J. , Mathai, Stephen C. , Group, the PVDOMICS Study, Hill, Nicholas S , Frantz, Robert P , Mathai, Stephen C , Rosenzweig, Erika B. , Hemnes, Anna R. , Desai, Ankit A. , Leopold, Jane A. , Horn, Evelyn M. , Frantz, Robert P. , Rischard, Franz , Hassoun, Paul M. , Group, the PVDOMICS Study

Pulmonary Circulation | August 22, 2023 | Volume: 13 | Issue: 3 | Pages: No page available

10.1002/pul2.12281 | PMID 37614830 Get It

AbstractThe prevalence of acute vasodilator response (AVR) to inhaled nitric oxide (iNO) during right heart catheterization (RHC) is 12% in idiopathic pulmonary arterial hypertension (IPAH). AVR, however, is reportedly lower in other disease‐associated pulmonary arterial hypertension (PAH), such as connective tissue disease (CTD). The prevalence of AVR in patients on PAH therapy (prevalent cases) is unknown. We sought to determine AVR prevalence in Group 1 PH in the PVDOMICS cohort of incident and prevalent patients undergoing RHC. AVR was measured in response to 100% O2 and O2 plus iNO, with positivity defined as (1) decrease in mean pulmonary artery pressure (mPAP) by ≥10 mmHg to a value ≤40 mmHg, with no change or an increase in cardiac output (definition 1); or (2) decrease in mPAP by ≥12% and pulmonary vascular resistance by ≥30% (definition 2). AVR rates and cumulative survival were compared between incident and prevalent patients. In 338 mainly prevalent (86%) patients, positive AVR to O2‐only was <2%, and 5.1% to 16.9%, based on definition 1 and 2 criteria, respectively; following O2 + iNO. IPAH AVR prevalence (4.1%–18.7%) was similar to prior reports. AVR positivity was 7.7% to 15.4% in mostly CTD‐PAH prevalent cases, and 2.6% to 11.8% in other PAH groups. Survival was 89% in AVR responders versus 77% in nonresponders from PAH diagnosis, and 91% versus 86% from PVDOMICS enrollment (log‐rank test p = 0.04 and p = 0.05, respectively). In conclusion, AVR in IPAH patients is similar to prior studies. AVR in non‐IPAH patients was higher than previously reported. The relationship between PAH therapy, AVR response, and survival warrants further investigation.
P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS
Shamsuzzaman, Md, Basudhar, Debashree, Takhar, Mandeep, Kostić, Ana , Campbell, Timothy , Manier, Salomon , Lin, Yi, Martin, Nathan , Mashadi-Hossein, Afshin , Rytlewski, Julie

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e1004207

10.1097/01.hs9.0000970140.10042.07 Get It

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
Mateos, María‐Victoria , Martin, Tom, Stewart, Keith, Diels, Joris , Thilakarathne, Pushpike, Perualila, Nolen Joy , Cabrieto, Jedelyn, Erler-Yates, Nichola, Jackson, Carolyn C. , Schecter, Jordan M. , Strulev, Vadim, Haddad, Imène , Filho, Octavio Costa, Pacaud, Lida , Weisel, Katja C , Berdeja, Jesús G. , Jakubowiak, Andrzej , Jagannath, Sundar , Lin, Yi , Ghilotti, Francesca , Einsele, Hermann , Moreau, Philippe

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e641482c

10.1097/01.hs9.0000970592.64148.2c Get It

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
Delforge, Michel , Patel, Krina K. , Eliason, Laurie , Dhanda, Devender , Shi, Ling , Guo, Shien, Arnulf, Bertrand , Manier, Salomon , McKiver, Mihaela Popa, Marshall, Thomas, Cavo, Michèle , Nooka, Ajay K. , Callander, Natalie S. , Giralt, Sergio , Einsele, Hermann , Ailawadhi, Sikander , Cook, Mark , Rodríguez‐Otero, Paula

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e031009e

10.1097/01.hs9.0000970524.03100.9e Get It

P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Hurd, David D., Voorhees, Peter M. , Rodriguez, Cesar, Tuchman, Sacha, Korde, Neha , Safah, Hana, Bueno, Orlando F. , Feng, Zhongling, Rosenberg, Tanya, Pothacamury, Rajvineeth Kumar, Talati, Chetasi, Kumar, Shaji , Vij, Ravi, Weisel, Katja C , D’Souza, Anita , Teipel, Raphael , Chung, Alfred , Ross, Jeremy A. , Lee, Shane , Jin, Ziyi , Talati, Chetasi

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e0036307

10.1097/01.hs9.0000970352.00363.07 Get It

P921: ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS FOR RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Shreve, Jacob , Warsame, Rahma , Pritchett, Josh, Kapoor, Prashant , Fonder, Amie , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Charalampous, Charalampos , Buadi, Francis K. , Paludo, Jonas , Dingli, David , Shah, Meera , Leung, Nelson , Gertz, Morie A. , Broski, Stephen M. , Rajkumar, S. Vincent , Binder, Moritz

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e156011e

10.1097/01.hs9.0000970588.15601.1e Get It

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
Watts, Justin M. , Prince, Gabrielle T., Baratam, Praneeth , Stein, Anthony S. , Foran, James M. , Arellano, Martha , Sallman, David A. , Patel, Prapti A. , Kapsalis, Stephanie M., Garcia‐Manero, Guillermo , Fathi, Amir T. , DiNardo, Courtney D. , Roboz, Gail J. , Madanat, Yazan F. , Botton, Stéphane de , Marchione, Dylan M. , Bai, Xiaofei

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e75740ab

10.1097/01.hs9.0000969800.75740.ab Get It